Logo

CombiMatrix Rebuffed, Hyseq Remains in Favor in Bid for Variangenics

Jan 21, 2003

NEW YORK, Jan. 21 - Hyseq's bid to buy Variagenics is still a go after the attention of another suitor was rebuffed, Variagenics said today.

 

CombiMatrix, owned by Acacia Research Corporation, made an unsolicited merger bid for Variagenics, the company said. The proposal included a stock-for-stock merger.

 

Variagenics board of directors voted down the proposal and reaffirmed their intention of merging with Hyseq, according to the company.

 

Click here for more information.

Breaking News
The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.